Literature DB >> 23472940

Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behcet's disease.

M D Redondo-Pachón1, R Enríquez, A E Sirvent, E Andrada, R Noguera-Pons, I Millán, F Amorós.   

Abstract

Renal involvement is an unusual but significant Behcet´s disease (BD) complication and AA amyloidosis appears to be the most common etiology. IL-6 is a pro-inflammatory cytokine with an important role in AA amyloidosis development. Tocilizumab (TCZ) is a humanized anti-IL-6 receptor antibody that has emerged as an effective and specific treatment in AA amyloidosis secondary to chronic inflammatory disorders. We report on a patient diagnosed with BD who developed nephrotic syndrome caused by renal AA amyloidosis with an excellent response to TCZ therapy.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23472940     DOI： 10.3109/0886022X.2013.773913

Source DB:  PubMed          Journal:  Ren Fail        ISSN： 0886-022X            Impact factor:   2.606


  8 in total

Review 1.  Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review.

Authors:  Jurgen Sota; Donato Rigante; Giuseppe Lopalco; Bruno Frediani; Rossella Franceschini; Mauro Galeazzi; Florenzo Iannone; Gian Marco Tosi; Claudia Fabiani; Luca Cantarini
Journal:  Rheumatol Int       Date:  2017-07-27       Impact factor: 2.631

2.  Tocilizumab-induced remission of nephrotic syndrome accompanied by secondary amyloidosis and glomerulonephritis in a patient with rheumatoid arthritis.

Authors:  Shunsuke Yamada; Akihiro Tsuchimoto; Yoshiki Kaizu; Masatomo Taniguchi; Kosuke Masutani; Hiroshi Tsukamoto; Hiroaki Ooboshi; Kazuhiko Tsuruya; Takanari Kitazono
Journal:  CEN Case Rep       Date:  2014-07-29

3.  Use of tocilizumab in amyloid a nephropathy associated with Sweet syndrome: a case report and literature review.

Authors:  D Giannese; F Ferro; D Moriconi; A G Bonadio; E Elefante; M F Egidi; A Cupisti; C Baldini
Journal:  CEN Case Rep       Date:  2020-07-17

Review 4.  Biological treatments in Behçet's disease: beyond anti-TNF therapy.

Authors:  Francesco Caso; Luisa Costa; Donato Rigante; Orso Maria Lucherini; Paolo Caso; Vittoria Bascherini; Bruno Frediani; Rolando Cimaz; Edoardo Marrani; Laura Nieves-Martín; Mariangela Atteno; Carmela G L Raffaele; Giusyda Tarantino; Mauro Galeazzi; Leonardo Punzi; Luca Cantarini
Journal:  Mediators Inflamm       Date:  2014-06-30       Impact factor: 4.711

Review 5.  Systemic AA amyloidosis: epidemiology, diagnosis, and management.

Authors:  Diego Real de Asúa; Ramón Costa; Jose María Galván; María Teresa Filigheddu; Davinia Trujillo; Julen Cadiñanos
Journal:  Clin Epidemiol       Date:  2014-10-29       Impact factor: 4.790

Review 6.  Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever.

Authors:  Serdal Ugurlu; Aysa Hacioglu; Yasaman Adibnia; Vedat Hamuryudan; Huri Ozdogan
Journal:  Orphanet J Rare Dis       Date:  2017-05-30       Impact factor: 4.123

Review 7.  Serum Amyloid A Protein-Associated Kidney Disease: Presentation, Diagnosis, and Management.

Authors:  Jordan Thorne; David Clark; Laurette Geldenhuys; Keigan More; Amanda Vinson; Karthik Tennankore
Journal:  Kidney Med       Date:  2022-06-26

8.  Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF.

Authors:  Sedat Yılmaz; Emre Tekgöz; Muhammet Çınar
Journal:  Eur J Rheumatol       Date:  2018-07-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.